1. Home
  2. QMLS vs CHRS Comparison

QMLS vs CHRS Comparison

Compare QMLS & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QMLS

QumulusAI Inc. Common Stock

N/A

Current Price

$5.79

Market Cap

210.4M

Sector

Technology

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.37

Market Cap

177.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QMLS
CHRS
Founded
N/A
2010
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
210.4M
177.7M
IPO Year
2025
2014

Fundamental Metrics

Financial Performance
Metric
QMLS
CHRS
Price
$5.79
$1.37
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
352.2K
1.3M
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.31
$1.09
52 Week High
$14.82
$2.62

Technical Indicators

Market Signals
Indicator
QMLS
CHRS
Relative Strength Index (RSI) 32.85 50.32
Support Level $5.52 $1.34
Resistance Level $7.72 $1.46
Average True Range (ATR) 0.71 0.09
MACD 0.15 0.01
Stochastic Oscillator 13.91 70.00

Price Performance

Historical Comparison
QMLS
CHRS

About QMLS QumulusAI Inc. Common Stock

QumulusAI Inc is a cloud infrastructure company engaged in the rapid deployment of graphics processing unit (GPU)-powered solutions for artificial intelligence (AI) applications, serving a critical market that is often overlooked by large-scale cloud providers (hyperscalers), which operate massive, standardized computing infrastructures serving the immense enterprises. The platform delivers flexible, competitively priced, and customizable solutions for underserved small- and mid-market customers, including machine learning teams, AI infrastructure startups, and research institutions, and also supports the scale and complexity requirements of large enterprises. Its products are B300 SXM6, B200 SXM, RTX Pro 6000, H200 SXM, and Others. Its solutions are Enterprise, Research, and AI Startups.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: